侵袭性变异型甲状腺微小乳头状癌与高危特征相关但未降低生存
该研究基于美国国家癌症数据库2004-2015年数据,比较经典型与侵袭性变异型(高细胞型、弥漫硬化型)甲状腺微小乳头状癌的病理特征和总生存。结果显示侵袭性变异型更常出现甲状腺外侵犯和淋巴结转移,但倾向性匹配后总生存无差异。
要点
- 高细胞型和弥漫硬化型微小乳头状癌更易出现甲状腺外侵犯和淋巴结转移。
- 高细胞型是甲状腺外侵犯和淋巴结转移的独立预测因素。
- 尽管病理特征更具侵袭性且治疗更积极,匹配后总生存与经典型无差异。
核心结论
- 高细胞型和弥漫硬化型甲状腺微小乳头状癌虽具更侵袭性病理特征且治疗更积极,但倾向性匹配后总生存与经典型无差异。
研究设计与样本
- 回顾性队列研究,纳入美国国家癌症数据库2004-2015年≥18岁、肿瘤≤1 cm的甲状腺乳头状癌患者。
- 共纳入82,056例经典型、923例高细胞型和219例弥漫硬化型甲状腺微小乳头状癌患者。
- 采用Kaplan-Meier法和倾向性匹配分析总生存,匹配变量包括临床病理和治疗因素。
主要发现
- 高细胞型和弥漫硬化型较经典型更常见甲状腺外侵犯和淋巴结受累(P < .01)。
- 高细胞型较经典型更常见远处转移(P = .02)。
- 多变量分析中,高细胞型(OR 4.19 [3.58-4.92],P < .001)和弥漫硬化型(OR 2.76 [1.92-3.97],P < .01)是甲状腺外侵犯的预测因素。
- 高细胞型是淋巴结转移的独立预测因素(OR 1.51 [1.25-1.83],P < .01)。
- 高细胞型和弥漫硬化型患者更常接受全甲状腺切除和放射性碘治疗。
临床怎么用
- 对于高细胞型或弥漫硬化型甲状腺微小乳头状癌,应认识到其更高的甲状腺外侵犯和淋巴结转移风险。
- 尽管总生存无差异,但这类变异型可能需要更积极的治疗策略,需结合个体情况决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study compares pathologic features and overall survival of classic versus aggressive variants of papillary thyroid microcarcinoma (PMTC). METHODS: Patients ≥18 years in the National Cancer Data Base (2004-2015) with the subtypes of classic (cPTMC), tall cell (mTCV), or diffuse sclerosing (mDSV) PTC (≤1 cm) were identified. Overall survival was analyzed by Kaplan-Meier and propensity matched for clinicopathologic and treatment variables. RESULTS: There were 82,056 cPTMC patients, 923 mTCV, and 219 mDSV. Extrathyroidal extension and nodal involvement were more frequent in mTCV and mDSV versus cPTMC (P < .01). mTCV had more distant metastases than cPTMC (P = .02). On multivariable analysis, mTCV (odds ratio 4.19 [3.58-4.92], P < .001) and mDSV (odds ratio 2.76 [1.92-3.97]; P < .01) histologies were predictors of extrathyroidal extension. mTCV was an independent predictor of nodal metastases (odds ratio 1.51 [1.25-1.83], P < .01). Total thyroidectomy and radioactive iodine treatment were more commonly used in mTCV and mDSV patients when compared with cPTMC patients. Despite more aggressive features and more aggressive treatment in mTCV and mDSV patients, there was no difference in overall survival when compared with propensity-matched cPTMC patients. CONCLUSION: Although mTCV and mDSV have more aggressive pathologic features and were treated more aggressively, there were no differences in overall survival compared with propensity-matched cPTMC patients.
引用
- Holoubek SA, Yan H, Khokar AH, et al. Aggressive variants of papillary thyroid microcarcinoma are associated with high-risk features, but not decreased survival. Surgery. 2019. PMID: 31627846. doi:10.1016/j.surg.2019.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。